Rhenman & Partners Asset Management AB
Latest statistics and disclosures from Rhenman & Partners Asset Management AB's latest quarterly 13F-HR filing:
- Top 5 stock holdings are UNH, CVS, AZN, MRK, LLY, and represent 14.20% of Rhenman & Partners Asset Management AB's stock portfolio.
- Added to shares of these 10 stocks: AZN (+$29M), MRK (+$27M), UNH (+$20M), JNJ (+$18M), CNC (+$16M), DHR (+$12M), DXCM (+$11M), SYRE (+$11M), ALGN (+$9.4M), NRIX (+$9.0M).
- Started 21 new stock positions in ORKA, TGTX, ERAS, TXG, ASND, AMN, MRK, MMED, AGL, MEDP. TNDM, MBX, SYRE, ASTH, DXCM, PRVA, CNC, AZN, MOH, JNJ, BCAX.
- Reduced shares in these 10 stocks: LLY (-$14M), REGN (-$13M), VEEV (-$12M), ADPT (-$10M), IQV (-$9.0M), MDGL (-$8.6M), NUVL (-$8.3M), OSCR (-$7.6M), BSX (-$7.4M), VRTX (-$6.4M).
- Sold out of its positions in ADPT, APGE, Ascendis Pharma A S, CMPX, ESPR, IMCR, IQV, NUVL.
- Rhenman & Partners Asset Management AB was a net buyer of stock by $165M.
- Rhenman & Partners Asset Management AB has $1.1B in assets under management (AUM), dropping by 30.71%.
- Central Index Key (CIK): 0001599882
Tip: Access up to 7 years of quarterly data
Positions held by Rhenman & Partners Asset Management AB consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rhenman & Partners Asset Management AB
Rhenman & Partners Asset Management AB holds 99 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| UnitedHealth (UNH) | 3.7 | $39M | +105% | 94k | 415.63 |
|
| CVS Caremark Corporation (CVS) | 2.7 | $29M | -16% | 279k | 103.45 |
|
| Astrazeneca Ord (AZN) | 2.7 | $29M | NEW | 152k | 187.99 |
|
| Merck & Co (MRK) | 2.6 | $27M | NEW | 214k | 128.50 |
|
| Eli Lilly & Co. (LLY) | 2.5 | $27M | -33% | 22k | 1199.43 |
|
| Abbvie (ABBV) | 2.3 | $24M | +35% | 97k | 251.64 |
|
| Alignment Healthcare (ALHC) | 2.2 | $24M | -5% | 997k | 23.81 |
|
| Edwards Lifesciences (EW) | 2.2 | $24M | +59% | 260k | 90.46 |
|
| Gilead Sciences (GILD) | 2.1 | $23M | +6% | 178k | 126.34 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 2.0 | $21M | +15% | 87k | 240.97 |
|
| Biogen Idec (BIIB) | 1.9 | $21M | -13% | 95k | 216.06 |
|
| Stryker Corporation (SYK) | 1.9 | $21M | +35% | 65k | 314.84 |
|
| Boston Scientific Corporation (BSX) | 1.8 | $19M | -27% | 451k | 42.68 |
|
| Johnson & Johnson (JNJ) | 1.7 | $18M | NEW | 73k | 253.97 |
|
| Guardant Health (GH) | 1.6 | $17M | -20% | 115k | 150.03 |
|
| Regeneron Pharmaceuticals (REGN) | 1.6 | $17M | -43% | 27k | 623.54 |
|
| Glaukos (GKOS) | 1.6 | $17M | +41% | 119k | 139.76 |
|
| BioMarin Pharmaceutical (BMRN) | 1.6 | $17M | +40% | 291k | 57.22 |
|
| Nurix Therapeutics (NRIX) | 1.6 | $17M | +118% | 684k | 24.26 |
|
| Natera (NTRA) | 1.6 | $17M | +18% | 61k | 271.45 |
|
| Mirum Pharmaceuticals (MIRM) | 1.5 | $16M | +50% | 139k | 117.07 |
|
| Insmed Com Par $.01 (INSM) | 1.5 | $16M | -4% | 152k | 106.62 |
|
| Tenet Healthcare Corp Com New (THC) | 1.5 | $16M | +57% | 85k | 187.08 |
|
| Thermo Fisher Scientific (TMO) | 1.5 | $16M | -23% | 32k | 501.36 |
|
| Centene Corporation (CNC) | 1.5 | $16M | NEW | 244k | 64.19 |
|
| Axsome Therapeutics (AXSM) | 1.5 | $15M | 63k | 244.77 |
|
|
| Danaher Corporation (DHR) | 1.4 | $15M | +344% | 80k | 190.48 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.4 | $15M | -29% | 31k | 496.73 |
|
| Anteris Technologies Global (AVR) | 1.4 | $15M | +6% | 1.5M | 9.85 |
|
| Neurocrine Biosciences (NBIX) | 1.4 | $15M | -14% | 86k | 168.53 |
|
| Pennant Group (PNTG) | 1.3 | $14M | +34% | 372k | 36.95 |
|
| Intuitive Surgical Com New (ISRG) | 1.3 | $14M | -6% | 35k | 397.68 |
|
| Anthem (ELV) | 1.3 | $14M | +8% | 35k | 386.73 |
|
| Livanova SHS (LIVN) | 1.3 | $14M | +5% | 164k | 82.23 |
|
| AmerisourceBergen (COR) | 1.2 | $13M | -10% | 47k | 282.98 |
|
| Charles River Laboratories (CRL) | 1.2 | $13M | +120% | 57k | 226.79 |
|
| Ideaya Biosciences (IDYA) | 1.2 | $13M | +34% | 344k | 37.27 |
|
| McKesson Corporation (MCK) | 1.2 | $13M | 17k | 755.60 |
|
|
| Syndax Pharmaceuticals (SNDX) | 1.2 | $12M | +47% | 560k | 21.86 |
|
| Brightspring Health Svcs (BTSG) | 1.1 | $12M | +231% | 166k | 69.74 |
|
| Medtronic SHS (MDT) | 1.1 | $11M | +61% | 145k | 78.23 |
|
| Mineralys Therapeutics (MLYS) | 1.1 | $11M | +58% | 416k | 26.98 |
|
| Oscar Health Cl A (OSCR) | 1.1 | $11M | -40% | 392k | 28.52 |
|
| Royalty Pharma Shs Class A (RPRX) | 1.0 | $11M | -15% | 197k | 56.07 |
|
| Dex (DXCM) | 1.0 | $11M | NEW | 160k | 67.35 |
|
| Align Technology (ALGN) | 1.0 | $11M | +740% | 63k | 168.66 |
|
| Spyre Therapeutics Com New (SYRE) | 1.0 | $11M | NEW | 119k | 88.78 |
|
| Relay Therapeutics (RLAY) | 1.0 | $11M | +57% | 566k | 18.71 |
|
| Arrowhead Pharmaceuticals (ARWR) | 1.0 | $10M | -11% | 128k | 81.51 |
|
| Agilent Technologies Inc C ommon (A) | 0.9 | $10M | +200% | 75k | 132.83 |
|
| Nektar Therapeutics Com New (NKTR) | 0.9 | $9.9M | +139% | 141k | 69.81 |
|
| Alkermes SHS (ALKS) | 0.9 | $9.7M | +39% | 185k | 52.40 |
|
| Abbott Laboratories (ABT) | 0.8 | $8.7M | -14% | 96k | 90.74 |
|
| Dianthus Therapeutics (DNTH) | 0.8 | $8.4M | +5% | 86k | 97.48 |
|
| Procept Biorobotics Corp (PRCT) | 0.7 | $7.8M | -27% | 345k | 22.58 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.7 | $7.8M | +13% | 145k | 53.67 |
|
| Oruka Therapeutics (ORKA) | 0.7 | $7.6M | NEW | 80k | 95.17 |
|
| Encompass Health Corp (EHC) | 0.7 | $7.5M | +31% | 74k | 101.08 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.7 | $7.5M | +60% | 385k | 19.47 |
|
| Iovance Biotherapeutics (IOVA) | 0.7 | $7.1M | -17% | 1.7M | 4.16 |
|
| Bridgebio Pharma (BBIO) | 0.6 | $6.8M | 91k | 74.48 |
|
|
| Kura Oncology (KURA) | 0.6 | $6.5M | +117% | 592k | 10.97 |
|
| Insulet Corporation (PODD) | 0.6 | $6.4M | +200% | 42k | 152.25 |
|
| Erasca (ERAS) | 0.6 | $6.4M | NEW | 349k | 18.32 |
|
| Krystal Biotech (KRYS) | 0.6 | $6.1M | -2% | 16k | 371.67 |
|
| Stevanato Group S P A Ord Srs (STVN) | 0.5 | $5.5M | +11% | 306k | 18.07 |
|
| Astrana Health Com New (ASTH) | 0.5 | $5.5M | NEW | 119k | 46.41 |
|
| Cardinal Health (CAH) | 0.5 | $5.3M | -16% | 23k | 237.56 |
|
| Alnylam Pharmaceuticals (ALNY) | 0.5 | $5.2M | -50% | 17k | 301.03 |
|
| Molina Healthcare (MOH) | 0.5 | $5.0M | NEW | 22k | 228.70 |
|
| Viking Therapeutics (VKTX) | 0.5 | $5.0M | -20% | 128k | 39.01 |
|
| Cigna Corp (CI) | 0.5 | $4.8M | +117% | 17k | 275.68 |
|
| Ionis Pharmaceuticals (IONS) | 0.4 | $4.7M | -35% | 60k | 79.29 |
|
| AMN Healthcare Services (AMN) | 0.4 | $4.7M | NEW | 145k | 32.37 |
|
| Denali Therapeutics (DNLI) | 0.4 | $4.6M | -10% | 179k | 25.72 |
|
| Medpace Hldgs (MEDP) | 0.4 | $4.5M | NEW | 8.5k | 529.59 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.4 | $4.3M | -66% | 8.1k | 536.95 |
|
| Amgen (AMGN) | 0.4 | $4.3M | -21% | 12k | 362.12 |
|
| Sionna Therapeutics (SION) | 0.4 | $4.3M | +10% | 97k | 43.99 |
|
| Ascendis Pharma A/s Ord Shs (ASND) | 0.4 | $4.0M | NEW | 15k | 266.72 |
|
| Cooper Cos (COO) | 0.4 | $3.9M | +8% | 54k | 71.71 |
|
| Waystar Holding Corp (WAY) | 0.3 | $3.7M | -47% | 179k | 20.53 |
|
| Mbx Biosciences (MBX) | 0.3 | $3.4M | NEW | 62k | 55.20 |
|
| Vericel (VCEL) | 0.3 | $3.1M | 70k | 44.49 |
|
|
| Veeva Sys Cl A Com (VEEV) | 0.3 | $3.1M | -79% | 17k | 177.47 |
|
| Bicara Therapeutics (BCAX) | 0.2 | $2.6M | NEW | 88k | 29.69 |
|
| Steris Shs Usd (STE) | 0.2 | $2.4M | 12k | 210.57 |
|
|
| Ocular Therapeutix (OCUL) | 0.2 | $2.2M | -26% | 225k | 9.82 |
|
| Stoke Therapeutics (STOK) | 0.2 | $2.1M | -22% | 65k | 32.72 |
|
| Xenon Pharmaceuticals (XENE) | 0.2 | $2.0M | +18% | 33k | 60.36 |
|
| Doximity Cl A (DOCS) | 0.1 | $1.6M | -58% | 76k | 20.74 |
|
| Privia Health Group (PRVA) | 0.1 | $1.3M | NEW | 50k | 25.73 |
|
| Novocure Ord Shs (NVCR) | 0.1 | $1.1M | 70k | 15.15 |
|
|
| Minimed Group (MMED) | 0.1 | $822k | NEW | 55k | 14.95 |
|
| Alphatec Hldgs Com New (ATEC) | 0.1 | $735k | +21% | 85k | 8.65 |
|
| Agilon Health Com New (AGL) | 0.1 | $536k | NEW | 5.0k | 107.18 |
|
| 10x Genomics Cl A Com (TXG) | 0.0 | $326k | NEW | 8.5k | 38.34 |
|
| Tandem Diabetes Care Com New (TNDM) | 0.0 | $302k | NEW | 20k | 15.09 |
|
| Tg Therapeutics (TGTX) | 0.0 | $275k | NEW | 5.0k | 54.94 |
|
Past Filings by Rhenman & Partners Asset Management AB
SEC 13F filings are viewable for Rhenman & Partners Asset Management AB going back to 2013
- Rhenman & Partners Asset Management AB 2026 Q2 filed Aug. 13, 2026
- Rhenman & Partners Asset Management AB 2026 Q1 filed May 14, 2026
- Rhenman & Partners Asset Management AB 2025 Q4 filed Feb. 13, 2026
- Rhenman & Partners Asset Management AB 2025 Q3 filed Nov. 13, 2025
- Rhenman & Partners Asset Management AB 2025 Q2 filed Aug. 13, 2025
- Rhenman & Partners Asset Management AB 2025 Q1 filed May 14, 2025
- Rhenman & Partners Asset Management AB 2024 Q4 filed Feb. 13, 2025
- Rhenman & Partners Asset Management AB 2024 Q3 filed Nov. 13, 2024
- Rhenman & Partners Asset Management AB 2024 Q2 filed Aug. 13, 2024
- Rhenman & Partners Asset Management AB 2024 Q1 filed May 14, 2024
- Rhenman & Partners Asset Management AB 2023 Q3 restated filed Nov. 13, 2023
- Rhenman & Partners Asset Management AB 2023 Q3 filed Nov. 9, 2023
- Rhenman & Partners Asset Management AB 2023 Q2 filed Aug. 11, 2023
- Rhenman & Partners Asset Management AB 2023 Q1 filed May 12, 2023
- Rhenman & Partners Asset Management AB 2022 Q4 filed Feb. 13, 2023
- Rhenman & Partners Asset Management AB 2022 Q3 filed Nov. 14, 2022